Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INDP
INDP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INDP News
Biotech Stocks Surge with Akari Leading the Rally
5d ago
NASDAQ.COM
Indaptus Therapeutics Q1 Financial Analysis
May 15 2026
seekingalpha
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
Dec 29 2025
Globenewswire
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
Dec 29 2025
Newsfilter
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
Dec 24 2025
Benzinga
Indaptus Therapeutics Completes Board Restructuring and Raises $6 Million
Dec 24 2025
Benzinga
Indaptus Therapeutics Stock Soars 64.65% to $3.26 After Securities Agreement
Dec 24 2025
Benzinga
Indaptus Therapeutics Announces Reverse Stock Split
Jun 25 2025
Newsfilter
Indaptus Therapeutics Sets 1-for-28 Reverse Stock Split
Jun 25 2025
NASDAQ.COM
3 Penny Stocks to Watch Now, 6/24/25
Jun 24 2025
TipRanks
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Jun 24 2025
PRnewswire
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results
Jun 23 2025
Benzinga
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
Jun 23 2025
Benzinga
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
May 08 2025
Newsfilter
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Mar 20 2025
Newsfilter
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
Mar 18 2025
Benzinga
Show More News
